Clal Biotechnology Industries
VC Fund
Tel Aviv, Israel
Clal Biotechnology Industries is a leading Israeli life sciences investment company traded on the Tel Aviv Stock Exchange (TASE: CBI)
- Total investments:
- 18
- Last investment:
- Lead investor:
- 11%
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Clal Biotechnology Industries invests in
Health CareBiotechnologyMedical DeviceMedicalPharmaceutical
Stages Clal Biotechnology Industries invests in
Series AFunding RoundSeries BSeries DSeries E
Countries Clal Biotechnology Industries invests in
IsraelUnited States
Round sizes
Series A $4M–$55MSeries B $15M–$40M
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $4M–$55M
- Series B
- $15M–$40M
Investment Focus
Industry
- Health Care 13 (72%)
- Biotechnology 12 (67%)
- Medical Device 8 (44%)
- Medical 6 (33%)
- Pharmaceutical 5 (28%)
Stage
- Series A 4 (22%)
- Funding Round 3 (17%)
- Series B 2 (11%)
- Series D 2 (11%)
- Series E 2 (11%)
Country
- Israel 11 (61%)
- United States 4 (22%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Ofer Gonen
CEO
|
CEO | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| TytoCare is a mobile-health platform and device, allowing anyone to perform self physical examination and remote diagnosis.Tyto Care has three telehealth products: the TytoHome for consumers, TytoPro for professionals, and TytoClinic for remote point-of-care locations. All solutions are designed to replicate a facetious clinician visit andinclude a modular examination tool for examining the heart, lungs, skin, throat, ears, and body temperature; a complete telehealth platform for sharing exam data, conducting live video exams, and scheduling visits; a cloud-based data repository with analytics; and built-in guidance technology and machine learning algorithms to ensure accuracy and ease of use. TytoCare was founded by Dedi Gilad, Ofer Tzadik in 2012 with a vision to put health in the hands of the consumer. | $49M / Series E / Aug 03, 2023 | ||
| Sight Diagnostics is a blood diagnostic company that combines machine vision and AI to improve health through fast, convenient and accurate diagnostics. Developed over almost a decade of research, Sight’s technology combines the latest innovations in blood sample preparation, optics, chemistry, biology, physics and computer science.Sight’s firstproduct, Parasight*, has diagnosed malaria in close to 1 million tests across 24 countries. Sight OLO, Sight’s latest FDA 510(k) cleared blood analyzer, digitizes blood with only 2 drops of a finger prick or venous sample and provides lab-grade Complete Blood Count results in minutes. Sight has growing offices in the UK, the US and Israel, and commercial footprint on 5 continents.*Note: Parasight is not available for sale in the US and did not receive FDA clearance for use in the US. | $71M / Series D / Aug 05, 2020 | ||
| Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts. | $15M / Series B / Apr 29, 2020 | ||
| Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer. It offers potent vaccines and immunotherapies that enable precise targeting and delivery of immunogens directly to the lymphatic system, substantially enhancing the body's own system of immune defenses. | $33M / Series B / Oct 02, 2019 | ||
| Cadent Therapeutics is a precision neuroscience company developing novel medicines that tune and modulate brain rhythms to restore cognitive and motor function in patients with serious neurological disease. The company leverages its precision neuroscience approach combining target specificity, patient selection, drug design and optimization, andnovel quantitative endpoints to create first-in-class molecules to treat movement and cognitive disorders.It was founded in 2010 and headquartered in Cambridge, Massachusetts. | $40M / Series B / Nov 15, 2018 | ||
| Anchiano is a biopharmaceutical company that specializes in the development of Targeted Cancer Therapies for the treatment of numerous types of cancer. The Company's technology offers a safe and long-term treatment of cancer, with no adverse effects. BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of MolecularBiology at the Hebrew University of Jerusalem, based on technology developed by him over the past 25 years. The drug candidates developed by the Company are targeted and their goal is to selectively destroy the cancer cells without affecting healthy cells (‘Targeted Cancer Therapy'). The approach is based on the identification of target genes, such as H19, that are expressed only in cancerous tumors, and not in healthy cells, and on the use of those genes' regulatory sequences for the activation of a toxin inside the cancerous cells only, thus destroying them without harming healthy cells. BioCancell's leading drug candidate, BC-819, has completed a Phase IIb clinical trial for the treatment of bladder cancer, as well as additional clinical trials for other cancer indications. BioCancell’s Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuation of the success of pre-clinical studies that have examined the use of BC-821 as a treatment for several cancer indications | $23M / Post-IPO Equity / Apr 13, 2018 | ||
| Colospan is a clinical-stage medical device company developing proprietary technology for colorectal surgery to prevent anastomotic leaks and diverting colonic stomas. It has developed a product that protects the intestine after a colectomy and sealing of the intestine, which is performed in cases of severe intestinal inflammatory disease andcancer of the bowel or rectum. In places where the intestine has been sealed, leakage requiring prolonged hospitalization or repeat surgery on already weak patients is liable to occur. The company develops a device that prevents inner-body leaks after intestinal surgery. It also develops a silicone-based, tube-like device intended to prevent the leak of feces into the body cavity after surgery in the intestines or colon. Colospan's device is meant to prevent or delay the for need colostomy—the surgical creation of an external bypass for the intestine or colon following the removal of a diseased part. The company’s lead product is a single-use, temporary intraluminal bypass device designed to reduce contact between fecal matter and the anastomotic site.Colospan was founded in 2010 and is based in Kefar Sava, Israel. | $8M / Venture - Series Unknown / Oct 01, 2017 | ||
| Gamida Cell is dedicated to making a significant difference in the clinical practice of modern medicine by first creating, then tapping the regenerative power of therapeutic stem cells. Gamida Cell is a leader in the development of stem cell therapy technologies and products. The therapies are based on expanded populations of cord blood stem cells,for the treatment of illnesses with significant unmet clinical needs such as blood cancers, autoimmune and metabolic diseases as well as neutropenia. | $40M / Series F / Jun 19, 2017 | ||
| Pi-Cardia is a medical device start-up company developing a novel low profile catheter for the treatment of aortic stenosis. The company's proprietary technology is based on delivering mechanical impact for creating fractures in valve calcifications, without injuring the surrounding soft tissue. This treatment, which only takes severalseconds, is intended to increase the valve effective orifice area without the need to replace the valve. | $10M / Series C / Jan 07, 2016 | ||
| Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01. | $55M / Series A / Oct 01, 2015 | ||
| See all 18 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
Health Care Investors
48,627 investors
Biotech Investors
24,131 investors
Biotechnology Investors
21,397 investors
Medical Investors
21,234 investors
Medical Device Investors
12,432 investors
Health Care VC Funds
36,465 investors
Biotech VC Funds
20,850 investors
Biotechnology VC Funds
18,763 investors
Medical VC Funds
18,263 investors
FAQ
What does Clal Biotechnology Industries invest in?
Clal Biotechnology Industries invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series A and Funding Round stage. Most of the 18 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Clal Biotechnology Industries's check size?
Clal Biotechnology Industries typically joins rounds of $4M–$55M at Series A and $15M–$40M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Clal Biotechnology Industries participates in.
How do I contact Clal Biotechnology Industries?
Public channels for Clal Biotechnology Industries include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Clal Biotechnology Industries?
The team at Clal Biotechnology Industries includes Ofer Gonen (CEO). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
